Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY-GENE trial of candesartan versus placebo in asymptomatic genetic carriers of dilated cardiomyopathy
2021-004577-30Phase 3Active
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Dec 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing Candesartan with Placebo (2 arms). Primary endpoint: Progression to significant LVEF or LVEDV deterioration. Started Dec 2021; status: active.
02
Drugs
candesartan
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2021-004577-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004577-30.